Exclusive Interview with Prof. Eric A Singer
On August 21, 2025, Journal of Cancer Metastasis and Treatment (JCMT) conducted an interview with Editorial Board Member Prof. Eric A. Singer, a leading expert in urologic oncology. During the interview, Prof. Singer generously shared his personal career, research insights, and vision for the future of cancer care.
Prof. Singer discussed the importance of clinical trials and the transformative potential of Artificial Intelligence (AI) in oncology. He also offers valuable guidance for young physicians and researchers preparing to navigate the rapidly evolving, AI-driven landscape of modern medicine.
Watch the following video for expert insights from Prof. Eric A Singer:
Interview Questions:
Q1: Prof. Singer, thank you for joining us. Could you share your career journey and what motivated you to specialize in urologic oncology?
Q2: Your research spans clinical trials, patient outcomes, and healthcare equity. Which area do you believe has had the greatest impact on clinical practice?
Q3: Artificial Intelligence is rapidly gaining attention in oncology. How do you see its role evolving in the field of urologic cancer?
Q4: What advice would you give to young physicians and researchers who want to prepare themselves for the future of medicine using AI tools?
Q5: Do you think the use of Artificial Intelligence could reduce the need for traditional surgical or medical education for young researchers?
About the Interviewee:
Prof. Eric A Singer, Professor of Urology and Bioethics at The Ohio State University College of Medicine, Chief of the Division of Urologic Oncology at the OSU Comprehensive Cancer Center-James, Columbus, Ohio, USA. A Fellow of both the American College of Surgeons (FACS) and the American Society of Clinical Oncology (FASCO).
Prof. Singer specializes in robotic and minimally invasive surgery for kidney, bladder, and prostate cancers. His research focuses on developing novel therapeutic strategies for genitourinary malignancies through clinical trials, aiming to advance personalized cancer care that optimizes patient outcomes while preserving quality of life.
Editor: Frida Zhai
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Journal of Cancer Metastasis and Treatment
